Safety of factor VIII inhibitor bypass activity (FEIBA®):: 10-year compilation of thrombotic adverse events

被引:179
作者
Ehrlich, HJ
Henzl, MJ
Gomperts, ED
机构
[1] Baxter BioSci, A-1221 Vienna, Austria
[2] Baxter BioSci, Glendale, CA USA
关键词
adverse drug reaction reporting systems; blood coagulation factor inhibitors; factor VIII; product surveillance; safety; thrombosis;
D O I
10.1046/j.1365-2516.2002.00532.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Published and unpublished spontaneously reported thrombotic adverse events (AEs) in factor VIII inhibitor bypass activity (FEIBA((R)) ) recipients were compiled for the most recent 10-year period during which FEIBA((R)) units equivalent to 3.95 x 10(5) typical infusions were distributed worldwide. A total of 16 thrombotic AEs were documented over the 10-year period, corresponding to an incidence of 4.05 per 10(5) infusions (95% CI, 2.32-6.58 per 10(5) infusions). Disseminated intravascular coagulation (n =7) and myocardial infarction (n =5) were the most frequent thrombotic AEs. One fatality occurred in an 87-year-old metastatic cancer patient. In 13/16 (81%) patients known risk factors were present, most commonly FEIBA((R)) overdose in 8/16 (50%), obesity in 3/16 (19%) and serum lipid abnormalities in 2/16 (12%). These findings indicate that thrombotic AEs in FEIBA((R)) recipients are very rare. Recognition of risk factors and avoidance of FEIBA((R)) overdosage may avert thrombotic AEs.
引用
收藏
页码:83 / 90
页数:8
相关论文
共 36 条
  • [1] INHIBITORS IN HEMOPHILIA PATIENTS - CURRENT STATUS AND MANAGEMENT
    ALEDORT, L
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1994, 47 (03) : 208 - 217
  • [2] Aledort LM, 2000, THROMB HAEMOSTASIS, V83, P637
  • [3] Under-reporting of adverse drug reactions -: Estimate based on a spontaneous reporting scheme and a sentinel system
    Alvarez-Requejo, A
    Carvajal, A
    Bégaud, B
    Moride, Y
    Vega, T
    Arias, LHM
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (06) : 483 - 488
  • [4] Thrombotic thrombocytopenic purpura associated with clopidogrel.
    Bennett, CL
    Connors, JM
    Carwile, JM
    Moake, JL
    Bell, WR
    Tarantolo, SR
    McCarthy, LJ
    Sarode, R
    Hatfield, AJ
    Feldman, MD
    Davidson, CJ
    Tsai, HM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (24) : 1773 - 1777
  • [5] MANAGEMENT OF ANTERIOR COMPARTMENT SYNDROME IN 2 HIGH RESPONDER FACTOR-VIII INHIBITOR PATIENTS WITH ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE
    CHRISTIANSEN, SE
    INGERSLEV, J
    WALLEVIK, K
    FARSO, F
    HELMIG, O
    STENBJERG, S
    [J]. THROMBOSIS RESEARCH, 1986, 42 (05) : 707 - 712
  • [6] Manifestations of factor VIII inhibitor in the head and neck
    DellaCroce, FJ
    Kountakis, S
    Aguilar, EF
    [J]. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1999, 125 (11) : 1258 - 1261
  • [7] Ehrlich HJ, 1998, THROMB HAEMOSTASIS, V79, P242
  • [8] Green D, 1999, HAEMOPHILIA, V5, P11
  • [9] Magnetic resonance imaging of myocardial infarction during prothrombin complex concentrate therapy of hemophilia A
    Gruen, DR
    Winchester, PH
    Brill, PW
    Ramirez, E
    [J]. PEDIATRIC RADIOLOGY, 1997, 27 (03) : 271 - 272
  • [10] Hay CRM, 1997, THROMB HAEMOSTASIS, V78, P1463